LDL Target by Risk Category Interpreter
LDL Target by Risk Category Interpreter
Pick the cardiovascular risk category, enter the current and untreated LDL cholesterol, and see the ESC/EAS goal, whether it is met, and the percentage reduction still needed — including the rule most calculators leave out, that high and very high risk need a 50% fall from baseline as well as the absolute goal. The 2026 ACC/AHA goals are printed alongside.
Is the LDL cholesterol goal met?
Risk category + LDL-C → goal, met or not, % still neededVery high risk (previous myocardial infarction). Untreated LDL-C 190 mg/dL; on atorvastatin 40 mg, current LDL-C 98 mg/dL.
How the goal and the gap are worked out
For high and very high risk: LDL-C to reach = the lower of (absolute goal) and (50% of untreated LDL-C)
For moderate and low risk: LDL-C to reach = absolute goal
Further reduction needed (%) = (current − LDL-C to reach) ÷ current × 100, or 0 if already met
- absolute goal
- very high risk after a second event within two years: below 1.0 mmol/L (40 mg/dL); very high: below 1.4 (55); high: below 1.8 (70); moderate: below 2.6 (100); low: below 3.0 (116)
- 50% clause
- for high and very high risk the ESC/EAS goal is a reduction of at least 50% from baseline AND the absolute goal. A patient who starts at 2.4 mmol/L and falls to 1.3 has met 1.4 but not 50%
- current
- the percentage is of the CURRENT value, because that is what the next treatment step acts on; the reduction from baseline is shown separately
Worked example
Very high risk (previous myocardial infarction). Untreated LDL-C 190 mg/dL; on atorvastatin 40 mg, current LDL-C 98 mg/dL.
ESC/EAS very high risk goal: below 55 mg/dL
50% clause: half of 190 is 95 mg/dL. The absolute goal, 55, is the lower of the two, so 55 is the figure to reach
Reduction already achieved from baseline: (190 − 98) ÷ 190 = 48.4% — nearly the 50% clause, but the absolute goal is far off
Further reduction needed from now: (98 − 55) ÷ 98 × 100 = 43.9%
A gap of 30 to 49% on top of a statin → a second agent is usually needed; ezetimibe adds roughly a fifth, a PCSK9 inhibitor roughly half
On the 2026 ACC/AHA guideline the very high risk goal is the same number, 55 mg/dL
LDL-C goals by risk category: ESC/EAS and ACC/AHA side by side
| Category | ESC/EAS 2019, unchanged in the 2025 focused update | 2026 ACC/AHA |
|---|---|---|
| Very high, second event within 2 years on maximal statin | Below 1.0 mmol/L (40 mg/dL) — may be considered (IIb) | Not separately stated in the summaries checked |
| Very high | At least 50% reduction from baseline and below 1.4 mmol/L (55 mg/dL) | Below 55 mg/dL (1.4 mmol/L); non-HDL-C below 85 mg/dL (2.2 mmol/L) |
| High | At least 50% reduction from baseline and below 1.8 mmol/L (70 mg/dL) | Below 70 mg/dL |
| Moderate | Below 2.6 mmol/L (100 mg/dL) — should be considered (IIa) | Borderline or intermediate risk: below 100 mg/dL |
| Low | Below 3.0 mmol/L (116 mg/dL) — may be considered (IIb) | — |
ESC/EAS risk categories, in brief
| Category | Who is in it |
|---|---|
| Very high | Documented atherosclerotic cardiovascular disease, clinical or unequivocal on imaging; diabetes with target organ damage, three or more major risk factors, or long-standing early-onset type 1 diabetes; severe CKD (eGFR below 30); FH with atherosclerotic disease or another major risk factor; SCORE2 or SCORE2-OP 20% or more |
| High | A markedly raised single risk factor (total cholesterol above 8 mmol/L, LDL-C above 4.9 mmol/L, or blood pressure 180/110 or above); FH without other major risk factors; moderate CKD (eGFR 30 to 59); diabetes without target organ damage but with duration of 10 years or more or another risk factor; SCORE2 or SCORE2-OP 10 to below 20% |
| Moderate | Young people with diabetes of short duration and no other risk factors; SCORE2 or SCORE2-OP 2 to below 10% |
| Low | SCORE2 or SCORE2-OP below 2% |
A goal is two numbers for most patients who need one
The ESC/EAS dyslipidaemia guideline sets LDL cholesterol goals by cardiovascular risk category, and the 2025 focused update left them unchanged: below 1.4 mmol/L (55 mg/dL) for very high risk, below 1.8 mmol/L (70 mg/dL) for high risk, below 2.6 mmol/L (100 mg/dL) for moderate risk and below 3.0 mmol/L (116 mg/dL) for low risk. What changed in 2025 was how risk is estimated in people without established disease: SCORE2 and SCORE2-OP replaced SCORE, with 20% or more counting as very high, 10 to below 20% as high, 2 to below 10% as moderate and below 2% as low.
The part most often missed is that for high and very high risk the goal is two conditions, not one. The guideline asks for a reduction of at least 50% from the untreated baseline and the absolute goal. A patient with an untreated LDL-C of 2.4 mmol/L who reaches 1.3 mmol/L has met the absolute goal and missed the 50% one. This page asks for the baseline for that reason, and works to whichever of the two is stricter. The percentage it reports is the further fall needed from the current value, because that is what the next treatment step has to deliver; the reduction already achieved from baseline is shown underneath.
In the United States the 2018 AHA/ACC cholesterol guideline, which used LDL-C thresholds for adding therapy rather than goals, has been replaced by the 2026 ACC/AHA multisociety dyslipidemia guideline. That document brings goals back — below 55 mg/dL for very high risk, below 70 mg/dL for high risk and below 100 mg/dL for borderline or intermediate risk — and moves risk estimation to the PREVENT equations. The numbers now agree closely across the Atlantic. The categories do not, so the goal has to come from the same guideline as the category.
This page decides the goal and the gap. It does not decide the drug. The LDL percent reduction needed calculator sets a percentage against the ACC/AHA statin intensity definitions, and the Friedewald LDL calculator and Sampson-NIH LDL calculator give the LDL-C itself; at low LDL-C values Friedewald under-reads, which can make a goal look met when it is not. If familial hypercholesterolaemia is possible, score it with the Dutch Lipid Clinic Network FH score first, because FH moves the category.
Frequently asked questions
What is the LDL cholesterol target for very high cardiovascular risk?
In the ESC/EAS guideline, below 1.4 mmol/L (55 mg/dL) and a reduction of at least 50% from the untreated baseline, both. The 2026 ACC/AHA guideline also sets below 55 mg/dL for very high risk, with non-HDL-C below 85 mg/dL. A goal below 1.0 mmol/L (40 mg/dL) may be considered after a second vascular event within two years on a maximally tolerated statin.
Why does the page ask for the untreated LDL cholesterol?
Because for high and very high risk the ESC/EAS goal is two conditions: at least a 50% fall from baseline and the absolute goal. Without the baseline, half of that goal cannot be checked. If the patient is untreated, enter the same value twice.
Did the 2025 ESC/EAS update change the LDL targets?
No. The focused update left the LDL-C goals as they were in 2019. It changed risk estimation to SCORE2 and SCORE2-OP, named Lp(a) above 50 mg/dL as a risk factor, and extended some drug recommendations, including bempedoic acid for statin-intolerant patients.
Is the 2018 AHA/ACC cholesterol guideline still current?
No. It was replaced in March 2026 by the ACC/AHA multisociety guideline on the management of dyslipidemia, which reintroduces LDL-C and non-HDL-C goals and uses the PREVENT risk equations in place of the Pooled Cohort Equations.
Related calculators
References
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
- Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359–4378. doi:10.1093/eurheartj/ehaf190.
- Guasti L, Gaudio GV, Lupi A. What is new in the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. ESC CardioPractice, European Society of Cardiology, 2 December 2025.
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. Published online 13 March 2026. doi:10.1016/j.jacc.2025.11.016. Also in Circulation, doi:10.1161/CIR.0000000000001423.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC multisociety guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082–e1143. Superseded by the 2026 ACC/AHA dyslipidemia guideline.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.